Loading stock data…
Veracyte, Inc. (VCYT)
$42.45-0.08 (-0.19%)
Market ClosedLast close Sep 8
Veracyte, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veracyte, Inc. in the Healthcare sector is trading at $42.45 with a market capitalization of $3.3B. Wall Street consensus targets $57.82 (11 analysts), implying a +36.2% move over the next 12 months. The stock is currently 30% below its 52-week high of $60.91, remaining 0.5% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $150.32M↑ | $139.07M↓ | $140.64M↑ | $131.87M↑ | $130.16M |
| Gross Profit | $108.55M↑ | $101.16M↓ | $101.97M↑ | $91.28M↑ | $89.77M |
| Operating Income | $22.98M↑ | $22.65M↓ | $39.91M↑ | $23.11M↑ | $15.24M |
| Net Income | $25.49M↓ | $28.71M↓ | $41.15M↑ | $19.14M↑ | -$980,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.46
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.25%
Volume
Today's trading volume
944,169
Recent News
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Veracyte Q2 Earnings Call Highlights
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD recurrence-monitoring test for muscle-invasive bladder cancer. Chief Executive Officer Marc Stapley
Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?
Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our latest analysis for Veracyte. The earnings beat and higher 2026 revenue guidance have coincided with strong momentum in Veracyte’s stock. The latest share price of US$59.78 reflects a 90 day share price return of 80.66%, while the 1 year total shareholder return is 152.88%. If Veracyte’s results...